blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1931369

EP1931369 - Aromatic-cationic peptide for use in a method for reducing CD36 expression [Right-click to bookmark this link]
Former [2008/25]METHODS FOR REDUCING CD36 EXPRESSION
[2015/04]
StatusNo opposition filed within time limit
Status updated on  23.06.2017
Database last updated on 02.07.2024
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
New state(s): IS		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
Cornell Research Foundation, Inc.
395 Pine Tree Road, Suite 310
Ithaca, NY 14850 / US
[2014/26]
Former [2008/25]For all designated states
Cornell Research Foundation Inc.
20 Thornwood Avenue
Ithaca, NY 14850 / US
Inventor(s)01 / SZETO, Hazel, H.
50 East 89th Street
Apartment 25A
New York, NY 10128 / US
02 / LIU, Shaoyi
209B E. Harriet Avenue
Palisades Park, NJ 07650 / US
03 / CHO, Sunghee
555 Central Park Avenue, Unit 125
Scaresdale, New York 10583 / US
 [2016/33]
Former [2008/28]01 / SZETO, Hazel, H.
50 East 89th Street Apartment 25A
New York, NY 10128 / US
02 / LIU, Shaoyi
209B E. Harriet Avenue
Palisades Park, NJ 07650 / US
03 / CHO, Sunghee
555 Central Park Avenue, Unit 125
Scaresdale, New York 10583 / US
Former [2008/25]01 / SZETO, Hazel, H.
50 East 89th Street Apartment 25A
New York, NY 10128 / US
02 / LIU, Shaoyi
209B E. Harriet Avenue
Palisades Park, NJ 07650 / US
03 / CHO, Sunghee
New York, NY
New York / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2013/12]Duckworth, Timothy John, et al
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2011/23]Thurgood, Alexander John
IP Galore 4, rue Durette
63500 Brenat / FR
Former [2011/23]Thurgood, Alexander John
Cabinet Richebourg "Le Clos du Golf" 69, rue Saint-Simon
42000 Saint-Etienne / FR
Former [2008/25]Thurgood, Alexander John
Cabinet Michel Richebourg 69, rue Saint-Simon Le Clos du Golf
42000 Saint-Etienne / FR
Application number, filing date06814864.218.09.2006
[2008/25]
WO2006US36291
Priority number, dateUS20050718170P16.09.2005         Original published format: US 718170 P
[2008/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007035640
Date:29.03.2007
Language:EN
[2007/13]
Type: A2 Application without search report 
No.:EP1931369
Date:18.06.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 29.03.2007 takes the place of the publication of the European patent application.
[2008/25]
Type: B1 Patent specification 
No.:EP1931369
Date:17.08.2016
Language:EN
[2016/33]
Search report(s)International search report - published on:US22.11.2007
(Supplementary) European search report - dispatched on:EP29.03.2012
ClassificationIPC:A61K38/00, A61K38/03, A61K38/07
[2012/18]
CPC:
A61K38/08 (EP,CN,KR,US); A61K38/07 (CN,KR,US); C07K5/101 (KR,US);
A61K38/03 (EP,KR,US); A61K38/06 (EP,US); A61K38/10 (KR);
A61K48/00 (KR); A61P13/02 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP,US); A61P43/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07K14/705 (EP,KR,US);
C07K5/1008 (EP,KR,US); C07K5/1016 (EP,KR,US); C07K5/1019 (EP,KR,US);
C07K5/1024 (EP,KR,US); A61K38/00 (EP,US) (-)
C-Set:
A61K38/07, A61K2300/00 (CN)
Former IPC [2008/25]A61K38/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/33]
Former [2008/25]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:Aromatisches kationisches Peptid zur Anwendung in einem Verfahren zum Reduzieren der CD36-Expression[2015/04]
English:Aromatic-cationic peptide for use in a method for reducing CD36 expression[2016/11]
French:Peptide aromatique-cationique pour utilisation dans une méthode pour réduire l'expression de CD36[2016/11]
Former [2008/25]VERFAHREN ZUM REDUZIEREN DER CD36-EXPRESSION
Former [2008/25]METHODS FOR REDUCING CD36 EXPRESSION
Former [2008/25]METHODES PERMETTANT DE REDUIRE L'EXPRESSION DE CD36
Entry into regional phase31.03.2008National basic fee paid 
31.03.2008Search fee paid 
31.03.2008Designation fee(s) paid 
31.03.2008Examination fee paid 
Examination procedure31.03.2008Examination requested  [2008/25]
04.12.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.02.2013Amendment by applicant (claims and/or description)
19.11.2013Despatch of a communication from the examining division (Time limit: M06)
06.05.2014Reply to a communication from the examining division
02.09.2015Despatch of a communication from the examining division (Time limit: M02)
02.11.2015Reply to a communication from the examining division
02.03.2016Communication of intention to grant the patent
05.07.2016Fee for grant paid
05.07.2016Fee for publishing/printing paid
05.07.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16176957.5  / EP3095454
EP17172250.7  / EP3260127
EP19160103.8  / EP3549594
EP20167024.7  / EP3725324
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.11.2013
Opposition(s)18.05.2017No opposition filed within time limit [2017/30]
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
12.02.2013Request for further processing filed
12.02.2013Full payment received (date of receipt of payment)
Request granted
20.02.2013Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
12.02.2013Request for further processing filed
12.02.2013Full payment received (date of receipt of payment)
Request granted
20.02.2013Decision despatched
Fees paidRenewal fee
25.09.2008Renewal fee patent year 03
25.09.2009Renewal fee patent year 04
27.09.2010Renewal fee patent year 05
26.09.2011Renewal fee patent year 06
25.09.2012Renewal fee patent year 07
27.09.2013Renewal fee patent year 08
29.09.2014Renewal fee patent year 09
28.09.2015Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.09.2006
AT17.08.2016
BE17.08.2016
CY17.08.2016
CZ17.08.2016
EE17.08.2016
ES17.08.2016
IS17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
RO17.08.2016
SI17.08.2016
SK17.08.2016
TR17.08.2016
BG17.11.2016
GR18.11.2016
PT19.12.2016
[2018/33]
Former [2018/29]HU18.09.2006
AT17.08.2016
BE17.08.2016
CY17.08.2016
CZ17.08.2016
EE17.08.2016
ES17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
RO17.08.2016
SI17.08.2016
SK17.08.2016
TR17.08.2016
BG17.11.2016
GR18.11.2016
PT19.12.2016
Former [2018/28]HU18.09.2006
AT17.08.2016
BE17.08.2016
CY17.08.2016
CZ17.08.2016
EE17.08.2016
ES17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
RO17.08.2016
SI17.08.2016
SK17.08.2016
BG17.11.2016
GR18.11.2016
PT19.12.2016
Former [2017/37]AT17.08.2016
BE17.08.2016
CZ17.08.2016
EE17.08.2016
ES17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
RO17.08.2016
SI17.08.2016
SK17.08.2016
BG17.11.2016
GR18.11.2016
PT19.12.2016
Former [2017/23]AT17.08.2016
BE17.08.2016
CZ17.08.2016
EE17.08.2016
ES17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
RO17.08.2016
SK17.08.2016
BG17.11.2016
GR18.11.2016
PT19.12.2016
Former [2017/13]AT17.08.2016
ES17.08.2016
LT17.08.2016
LV17.08.2016
PL17.08.2016
BE30.09.2016
GR18.11.2016
PT19.12.2016
Former [2017/12]AT17.08.2016
ES17.08.2016
LT17.08.2016
PL17.08.2016
BE30.09.2016
GR18.11.2016
PT19.12.2016
Former [2017/07]LT17.08.2016
Documents cited:Search[A]WO2004017986  (UNIV MONTREAL [CA], et al)[A] 4-19;
 [X]WO2004070054  (CORNELL RES FOUNDATION INC [US], et al) [X] 9 * claim 49 *;
 [X]WO2005072295  (CORNELL RES FOUNDATION INC [US], et al) [X] 9,10 * paragraph [0084] * * examples 18-20 * * claims 43, 50 *;
 [A]  - SYLVIE MARLEAU ET AL, "EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions", FEDERATION PROCEEDINGS, (20050825), doi:10.1096/FJ.04-3253FJE, pages 1 - 7, XP007914578 [A] 4-19 * page 7, paragraph 4 * * page 8, paragraph l *

DOI:   http://dx.doi.org/10.1096/fj.04-3253fje
 [A]  - ROBERTA RICCIARELLI ET AL, "Vitamin E Reduces the Uptake of Oxidized LDL by Inhibiting CD36 Scavenger Expression in Cultured Aortic Smooth Muscle Cells", CIRCULATION, (20000101), vol. 102, doi:10.1161/01.CIR.102.1.82, pages 82 - 87, XP055022280 [A] 1-3,20-22 * page 82, column l, paragraph l * * figures 1-3, 6 * * page 86, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1161/01.CIR.102.1.82
 [A]  - HRON-MILHAVET L ET AL, "Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice", ENDOCRINOLOGY, ENDOCRINE SOCIETY, US, (20041001), vol. 145, no. 10, doi:10.1210/EN.2003-1543, ISSN 0013-7227, pages 4667 - 4676, XP002392959 [A] 10-13 * abstract *

DOI:   http://dx.doi.org/10.1210/en.2003-1543
 [A]  - KATALIN SUSZTAK ET AL, "Multiple Metabolic Hits Converge on CD36 as Novel Mediator of Tubular Epithelial Apoptosis in Diabetic Nephropathy", PLOS MEDICINE, (20050101), vol. 2, no. 2, doi:10.1371/journal.pmed.0020045, ISSN 1549-1277, page E45, XP055020734 [A] 17-19

DOI:   http://dx.doi.org/10.1371/journal.pmed.0020045
 [XP]  - S Cho ET AL, "A cell-permeable antioxidant peptide attenuates CD36-mediated ischemic injury via normalizing redox state.", Neuroscience meeting planner, Society for Neuroscience, (20051114), URL: http://www.sfn.org/absarchive/abstract.aspx, (20120320), XP055022440 [XP] 20,22 * abstract *
 [AP]  - H H SZETO, "Mitochondria-Targeted Peptide Antioxidants: Novel Neuroprotective Agents", THE AAPS JOURNAL, (20060818), vol. 8, no. 3, pages E521 - E531, XP055020617 [AP] 1-22 * paragraph l - page E258, paragraph 1 *

DOI:   http://dx.doi.org/10.1208/aapsj080362
 [T]  - ADAM T HOYE ET AL, "Targeting mitochondria", ACCOUNTS OF CHEMICAL RESEARCH, ACS, WASHINGTON, DC, US, vol. 41, no. 1, doi:10.1021/AR700135M, ISSN 0001-4842, (20080501), pages 87 - 97, (20080115), XP002636704 [T] * column r, paragraph 5 * * page 91, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1021/AR700135M
 [T]  - SUNGHEE CHO ET AL, "A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 282, no. 7, doi:10.1074/JBC.M609388200, ISSN 0021-9258, (20070216), pages 4634 - 4642, (20061218), XP002638723

DOI:   http://dx.doi.org/10.1074/JBC.M609388200
 [T]  - SUNGHEE CHO ET AL, "CD36: A multi-modal target for acute stroke therapy", JOURNAL OF NEUROCHEMISTRY, (20090501), vol. 109, doi:10.1111/j.1471-4159.2009.05801.x, ISSN 0022-3042, pages 126 - 132, XP055020732

DOI:   http://dx.doi.org/10.1111/j.1471-4159.2009.05801.x
 [T]  - GIUNTA ET AL, "The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, (20070223), vol. 28, no. 4, doi:10.1016/J.NEUROBIOLAGING.2006.02.002, ISSN 0197-4580, pages 515 - 518, XP005901138

DOI:   http://dx.doi.org/10.1016/j.neurobiolaging.2006.02.002
International search[Y]US2005096333  (DUGAR SUNDEEP [US], et al);
 [Y]US2005192215  (GHOSH MALABIKA [US], et al);
 [Y]  - ZHAO ET AL., "Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling", J. BIOL. CHEM., (200408), vol. 279, no. 33, pages 34682 - 34690, XP002594478

DOI:   http://dx.doi.org/10.1074/JBC.M402999200
 [Y]  - FUHRMAN ET AL., "Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of praoxonase", ATHEROSCLEROSIS, (20020307), vol. 161, no. 2, pages 307 - 316, XP008126611
Examination   - ALAIN GELOEN ET AL, "CD36 Inhibitors Reduce Postprandial Hypertriglyceridemia and Protect against Diabetic Dyslipidemia and Atherosclerosis", PLOS ONE, (20120525), vol. 7, no. 5, doi:10.1371/journal.pone.0037633, XP055087921

DOI:   http://dx.doi.org/10.1371/journal.pone.0037633
    - JAMES SCOTT HALE ET AL, "Context Dependent Role of the CD36 - Thrombospondin - Histidine-Rich Glycoprotein Axis in Tumor Angiogenesis and Growth", PLOS ONE, (20120710), vol. 7, no. 7, doi:10.1371/journal.pone.0040033, XP055087924

DOI:   http://dx.doi.org/10.1371/journal.pone.0040033
by applicantWO02083106
    - FEBBRAIO M; PODREZ EA; SMITH JD; HAJJAR DP; HAZEN SL ET AL., "Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice", J CLINICAL INVESTIGATION, (2000), vol. 105, doi:doi:10.1172/JCI9259, pages 1049 - 1056, XP002487573

DOI:   http://dx.doi.org/10.1172/JCI9259
    - FEBBRAIO M.; HAJJAR DP; SILVERSTEIN RL., "CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism", JOURNAL OF CLINICAL INVESTIGATION, (2001), vol. 108, pages 785 - 791, XP002487577
    - "Solid Phase Peptide Synthesis", Methods Enzymol., ACADEMIC PRESS, INC, (1997), page 289
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.